GeoVax Labs initiated with a Buy at Roth MKM

Roth MKM initiated coverage of GeoVax Labs with a Buy rating and $20 price target. GeoVax is engaged in developing novel vaccines and immunotherapies for underserved COVID-19 populations, Mpox/smallpox prevention, and select solid tumors such as head and neck squamous cell carcinoma, the analyst tells investors in a research note. The firm believes GEO-MVA is likely to be the company’s first product to market and that it would require about three years to commercialize the vaccine.